In the first set of experiments, a number of TAs were used to treat HeLa cells without plasmids, followed by infection with self-complementary (sc) AAV2 vectors carrying EGFP driven by a chicken β-actin/cytomegalovirus (CMV) hybrid promoter (CBAp) at an MOI of 2,000 viral genomes (vgs) per cell. Here, ACTB is linked to infection.